Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. (NRIX): 11 pipeline candidates · 2 upcoming catalysts · ~9 mo cash runway · 9 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
9.0 months
D/E 0.32 · 6% dilution
Lead: Phase 3
11 candidates
2 upcoming, next in ~2175d
0 buys · 18 sells (180d)
A transparent, data-derived signal for Nurix Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.8B
Cash
$72.2M
Quarterly Burn
$71.9M
Runway
9.0 mo
Revenue
$6.3M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (11 candidates)
| Drug | Phase |
|---|---|
| bexobrutideg | Phase 3 |
| Degrader Antibody Conjugates (DACs) programs | Preclinical |
| Esomeprazole | Phase 1 |
| NX-0479 / GS-6791 | — |
| NX-1607 | Phase 1 |
| NX-2127 | Phase 1 |
| NX-5948 | Phase 1 |
| obinutuzumab | Phase 1/Phase 2 |
| Pan-mutant BRAF degrader program (proprietary) | Preclinical |
| Pan-mutant BRAF program (mutant BRAF degraders) | Preclinical |
Showing 10 of 11 candidates. Sign up for full pipeline.
Upcoming Catalysts (2)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.8% historical Phase 3 primary-endpoint success rate (n=362)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
194
Total value held
$1.68B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 8,925,642 | $138.3M |
| vanguard capital management llc | 8,854,224 | $137.2M |
| perceptive advisors llc | 7,421,754 | $115.0M |
| deep track capital, lp | 6,345,244 | $98.4M |
| fmr llc | 5,541,271 | $85.9M |
| state street corp | 5,141,195 | $79.7M |
| morgan stanley | 4,931,999 | $76.4M |
| baker bros. advisors lp | 4,658,556 | $72.2M |
| general atlantic, l.p. | 4,101,865 | $63.6M |
| pictet asset management holding sa | 2,726,138 | $42.3M |
Showing top 10 of 194 institutional holders of Nurix Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Nurix Therapeutics, Inc.'s pipeline?
Nurix Therapeutics, Inc. (NRIX) has 11 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Nurix Therapeutics, Inc.'s lead drug candidate?
Nurix Therapeutics, Inc.'s most advanced tracked candidate is bexobrutideg (Phase 3) for Treatment of relapsed or refractory B-cell malignancies; being explored for autoimmune and inflammatory diseases. Phase 2 study in patients with relapsed or refractory CLL who failed three previous lines of therapy. Fast Track designation in CLL/SLL and WM..
What is Nurix Therapeutics, Inc.'s next catalyst?
Nurix Therapeutics, Inc.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Ref" — expected June 1, 2032.
What is Nurix Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Nurix Therapeutics, Inc. has approximately 9.0 months of cash runway.
What is Nurix Therapeutics, Inc.'s market capitalization?
Nurix Therapeutics, Inc.'s market capitalization is approximately $1.8B.
Get the full picture on Nurix Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.